FDA clears integrated system of LifeScan's smart blood glucose system, WellDoc's digital diabetes management platform

By Heather Mack
Share

The FDA has cleared the wireless integration of one of Johnson and Johnson subsidiary LifeScan’s blood glucose monitoring systems and WellDoc’s digital diabetes management platform for people with type 2 diabetes.

The two companies originally teamed up in March of this year. The integrated system consists of OneTouch Verio Flex, LifeScan’s Bluetooth smart blood glucose monitoring system and companion app, and WellDoc’s FDA-cleared mobile diabetes management platform, BlueStar.

Using blood glucose data from OneTouch, BlueStar’s platform identifies trends and patterns, sending information to the user’s healthcare team while offering the user individualized feedback in real time. It also offers virtual coaching based on their specific care plan, and the whole system works with the OneTouch Reveal mobile app.

The two companies are currently working with health plans to expand access to the integrated system.

"Our partnership with WellDoc highlights our sustained commitment in helping to drive better health outcomes by building a more connected patient experience,” LifeScan’s World Wide President Valerie Asbury said in a statement. “Integrating digital solutions such as OneTouch Reveal mobile app and BlueStar will help patients self-manage their diabetes and create value for health care providers.”